Narjust Duma, MD, and Gladys I. Rodriguez, MD, on A First for Hispanic Women: Formation of a YIA for Latinas
2021 ASCO Annual Meeting
Narjust Duma, MD, of the Carbone Cancer Center at the University of Wisconsin, Madison, and Gladys I. Rodriguez, MD, of South Texas Oncology and Hematology, talk about the underrepresentation of Hispanic individuals in medicine, especially in oncology, and their efforts to create the first Young Investigator Award in Recognition of an Outstanding Latina Researcher to encourage Hispanic women to enter medicine and cancer research.
The ASCO Post Staff
Martin Reck, MD, PhD, of LungenClinic, discusses a 2-year update of the CheckMate 9LA study, which sought to determine whether nivolumab plus ipilimumab combined with two cycles of chemotherapy is more effective than four cycles of chemotherapy alone as a first-line treatment for patients with stage IV non–small cell lung cancer (Abstract 9000).
The ASCO Post Staff
Brian K. Link, MD, of the University of Iowa Carver College of Medicine, reviews three abstracts on state-of-the-art therapies for mantle cell lymphoma: bendamustine, rituximab, lenalidomide and bortezomib; treatment patterns and outcomes for previously untreated patients; and venetoclax, lenalidomide, and rituximab in newly diagnosed disease (Abstracts 7503, 7504, and 7505).
The ASCO Post Staff
Nadia Harbeck, MD, PhD, of Ludwig Maximilian University of Munich, discusses results from the ADAPT HR–/HER2+ trial, which showed, for the first time, improved pathologic complete response and survival in patients with early breast cancer who were treated weekly with a de-escalated 12-week regimen of neoadjuvant paclitaxel plus pertuzumab and trastuzumab (Abstract 503).
The ASCO Post Staff
Thierry André, MD, of Hôpital Saint-Antoine, discusses final overall survival data for the phase III KEYNOTE-177 study, which confirmed pembrolizumab as a new standard of care for first-line treatment of patients with microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer (Abstract 3500).
The ASCO Post Staff
Geoffrey J. Lindeman, MBBS, PhD, of Peter MacCallum Cancer Centre, discusses results from the phase II VERONICA study, which compared venetoclax plus fulvestrant with fulvestrant alone in women with estrogen receptor–positive, HER2-negative, locally advanced or metastatic breast cancer who experienced disease recurrence or progression during or after treatment with CDK4/6 inhibitor therapy (Abstract 1004).
